National Coverage Analysis (NCA) Tracking Sheet for Aprepitant for Chemotherapy-Induced Emesis (CAG-00248R)
Aprepitant (Emend®) is an orally administered neurokinin-1 antagonist that is proposed to function in combination with other oral anti-emetics specifically for patients receiving highly or moderately emetogenic chemotherapy.
In April 2005, the Centers for Medicare and Medicaid Services (CMS) published a National Coverage Decision (NCD) for Aprepitant for Chemotherapy-Induced Emesis (110.18). At that time, CMS determined that the evidence was adequate to conclude that the oral anti-emetic three drug combination of aprepitant (Emend®), a 5-HT3 antagonist, and dexamethasone is reasonable and necessary for patients who are receiving one or more of the following highly emetogenic anti-cancer chemotherapeutic agents:
CMS is reconsidering NCD 110.18 to review the evidence on the use of oral aprepitant (Emend®) in combination with dexamethasone and a 5-HT3 antagonist in patients receiving moderately emetogenic anti-cancer chemotherapeutic agents
National Coverage Analysis (NCA) Tracking Sheet for Aprepitant for Chemotherapy-Induced Emesis (CAG-00248R)
In April 2005, the Centers for Medicare and Medicaid Services (CMS) published a National Coverage Decision (NCD) for Aprepitant for Chemotherapy-Induced Emesis (110.18). At that time, CMS determined that the evidence was adequate to conclude that the oral anti-emetic three drug combination of aprepitant (Emend®), a 5-HT3 antagonist, and dexamethasone is reasonable and necessary for patients who are receiving one or more of the following highly emetogenic anti-cancer chemotherapeutic agents:
| - Carmustine, | - Cisplatin, | - Cyclophosphamide, |
| - Dacarbazine, | - Mechlorethamine, | - Streptozocin, |
| - Doxorubicin, | - Epirubicin, | - Lomustine |
.png)
No hay comentarios:
Publicar un comentario